Literature DB >> 14583136

Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation.

Naj A Sharif1, Julie Y Crider, Shahid Husain, Ismail Kaddour-Djebbar, Habib R Ansari, Ata A Abdel-Latif.   

Abstract

Phospholipase C induced phosphoinositide (PI) turnover, intracellular Ca(2+) ([Ca(2+)](i)) mobilization and mitogen-activated protein (MAP) kinase activation by FP-class prostaglandin analogs was studied in normal human ciliary muscle (h-CM) cells. Agonist potencies obtained in the PI turnover assays were: travoprost acid ((+)-fluprostenol; EC(50) = 2.6 +/- 0.8 nM) > bimatoprost acid (EC(50) = 3.6 +/- 1.2 nM) > (+/-)-fluprostenol (EC(50) = 4.3 +/- 1.3 nM) >> prostaglandin F(2 alpha) (PGF(2 alpha)) (EC(50) = 134 +/- 17 nM) > latanoprost acid (EC(50) = 198 +/- 83 nM) > S-1033 (EC(50) = 2930 +/- 1420 nM) > unoprostone (EC(50) = 5590 +/- 1490 nM) > bimatoprost (EC(50) = 9600 +/- 1100 nM). Agonist potencies in h-CM cells correlated well with those previously obtained for the cloned human ciliary body-derived FP receptor (r = 0.96, p< 0.001) and that present on h-TM cells (r = 0.94, p< 0.0001). Travoprost acid, PGF(2 alpha) and unoprostone also stimulated [Ca(2+)](i) mobilization in h-CM cells with travoprost acid being the most potent agonist. MAP kinase activity was stimulated in the h-CM cells with the following rank order of activity (at 100 nM): travoprost acid > PGF(2 alpha) > latanoprost acid > PGD(2) > bimatoprost > latanoprost = bimatoprost acid = fluprostenol > PGE(2) = S-1033 > unoprostone > PGI(2). The PI turnover, [Ca(2+)](i) mobilization and MAP kinase activation induced by several of these agonists was blocked by the FP receptor antagonist, AL-8810 (11 beta-fluoro-15-epiindanyl PGF(2 alpha)) (e.g. K(i) = 5.7 microM versus PI turnover). These studies have characterized the biochemical and pharmacological properties of the native FP prostaglandin receptor present on h-CM cells using three signal transduction mechanism assays and a broad panel of FP-class agonist analogs (including free acids of bimatoprost, travoprost and latanoprost) and the FP receptor antagonist, AL-8810.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583136     DOI: 10.1089/108076803322473006

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  15 in total

1.  Unoprostone activation of BK (KCa1.1) channel splice variants.

Authors:  Ling Yu; Amity F Eaton; Qiang Yue; Hui-Fang Bao; He-Ping Ma; John Cuppoletti; Douglas C Eaton
Journal:  Biochim Biophys Acta       Date:  2015-08-13

Review 2.  [Suprachoroidal minimally invasive glaucoma surgery : Procedures and clinical outcome].

Authors:  C Erb
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

3.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

4.  In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.

Authors:  Hee Young Choi; Ji Eun Lee; Ji Woong Lee; Hyun Jun Park; Ji Eun Lee; Jae Ho Jung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-22       Impact factor: 2.671

Review 5.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

6.  Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.

Authors:  B'Ann True Gabelt; Elizabeth A Hennes; Mark A Bendel; Chase E Constant; Mehmet Okka; Paul L Kaufman
Journal:  J Ocul Pharmacol Ther       Date:  2009-02       Impact factor: 2.671

7.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

8.  Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations.

Authors:  Emilio Rintaro Suzuki; Cibele Lima Belico Suzuki
Journal:  Clin Ophthalmol       Date:  2010-10-21

Review 9.  Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.

Authors:  Carol B Toris; B'Ann T Gabelt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2008-11       Impact factor: 6.048

10.  Role of PKCepsilon in PGF2alpha-stimulated MMP-2 secretion from human ciliary muscle cells.

Authors:  Shahid Husain; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2008-06       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.